<DOC>
	<DOCNO>NCT02761291</DOCNO>
	<brief_summary>Nasopharyngeal carcinoma ( NPC ) Epstein-Barr virus ( EBV ) relate malignancy endemic disease Southeast Asian country . EBV identify therapeutic target EBV related cancer lymphoma NPC . In cancer cell , EBV latent phase express 8-11 gene maintain EBV proliferation . After switch lytic phase , almost EBV encode gene express include thymidine kinase ( TK ) highly immunogenetic gene . These latent-lytic phase swifter include DNA methyltransferase inhibitor , various histone deacetylase ( HDAC ) inhibitor , radiotherapy chemotherapy . Recently , combine chemotherapy viral lytic therapy , cytolytic viral activation therapy ( CVAT ) show promising result pilot study NPC . In patient derive xenograft ( PDX ) animal model drug sensitivity screening , gemcitabine ( GEM ) show effective drug . Furthermore , CVAT GEM + Valproic acid ( VPA ) + ganciclovir ( GCV ) maintain chemotherapy may benefit reduce chemotherapy related side effect prolong treatment response duration . The following phase I clinical trial propose test optimal combination drug . 1 . Number patient : total 18 patient need 2 . Inclusion criterion : ( 1 ) use 2nd line regimen recurrence/metastasis NPC patient tissue prove World Health Organization ( WHO ) type II type III . ( 2 ) Performance status : eastern cooperative oncology group performance status ( ECOG PS ) ≤2 . 3 . Chemotherapy regimen : Gemcitabine ( GEM , TTY ) + Valproic acid ( VPA , generic medicine ) viral activation + Valganciclovir ( VGC , Roche ) antiviral medication 4 . This treatment cycle 28 day repeat maximum 6 time . ( Q4wks/cycle , max : 6 cycle ) 5 . Dosage : ( 1 ) GEM : 600 , 800 , 1000 , 1250 mg/m^2 , D1 &amp; D8 , intravenously . ( 2 ) VPA 12.5 mg/kg/day D1~14 , per o . ( 3 ) VGC ( 2-3 ) x 450 mg/day D9~15 , per o . 6 . Objectives : 1. primary : find best combination 3 drug recurrent/metastatic NPC patient . 2. second : evaluate response disease control rate pilot study . Key word : NPC , cytolytic viral activation therapy , gemcitabine , valproic acid , ganciclovir .</brief_summary>
	<brief_title>Study Cytolytic Viral Activation Therapy ( CVAT ) Recurrent/Metastatic Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>1 . Introduction investigational treatment ( ) study treatment ( ) 1.1 Overview gemcitabine Gemcitabine ( 29,29-difluoro 29-deoxycytidine , dFdC ) develop cytosine arabinoside ( Ara-C ) nucleoside analog use chemotherapy . It intend antiviral drug initial , preclinical testing show kill leukemia cell spectrum solid tumor vitro . In cell , gemcitabine undergoes complex intracellular conversion active form nucleotide gemcitabine diphosphate ( dFdCDP ) triphosphate ( dFdCTP ) influence DNA synthesis . dFdCTP compete deoxycytidine triphosphate ( dCTP ) dFdCDP potent inhibitor ribonucleoside reductase ( 1 ) . Gemcitabine administer intravenous route dose range 0.6-1.2 g/m^2 body surface area ( 2 ) , use broad spectrum cancer management include lung , breast , pancrease , bladder ( 3 ) . The toxic profile gemcitabine major hematopoietic system especially neutropenia thrombocytopenia ( 4 ) . In NPC treatment , gemcitabine focus several report , interest OR rate range 23—48 % median progression-free survival ( PFS ) 3.6 5.1 month ( 5 ) . In combination chemotherapy cisplatin , OR rate 42.7 73 % report median PFS 5.6 10.6 month ( 6 ) . In combined oxaliplatin , OR rate 56.1 % median PFS 9 month ( 6 ) . In combined vinorelbine , OR rate 36 37.7 % report median PFS 5.2 5.6 month . In multiple drug combination carboplatin , paclitaxel , 5-Fluoro-Uracil/LeucoVorin , high OR rate 86 % report median PFS 8 month ( 6 ) . Still trials do small series lack randomize large scale phase III trial . 1.2 Valproic acid ( VPA ) Valproic acid ( VPA ) , branch short-chain fatty acid , widely use clinical antiepileptic drug mood stabilizer , primarily treatment epilepsy , bipolar disorder , prevention migraine headache ( 7 ) . The antiepileptic property VPA attribute inhibition Gamma Amino Butyrate ( GABA ) trans aminobutyrate ion channel . VPA recently classify among Histone Deacetylase ( HDAC ) inhibitor , act directly level gene transcription inhibit histone deacetylation make transcription site accessible . Chromatin form DNA package nucleosome structure . The condensed form chromatin ( heterochromatin ) inactive term transcription whereas decondensed form ( euchromatin ) correspond active form . The histone acetylation lead relaxation nucleosome structure , release DNA allow transcription . Inhibition histone deacetylases ( HDACs ) promote decondensed chromatin formation , thereby promote expression gene ( 7 ) . Valproic acid ( VPA ) , HDAC inhibitor , specifically target class I , I b , II HDACs ( 8 ) . VPA also regulate expression proteins essential chromatin maintenance : Structural Maintenance chromatin ( SMC ) , DNA methyl transferase-1 ( DNMT1 ) , heterochromatin protein-1 ( HP1 ) ( 9 ) . VPA show induce histone 3 methylation would increase transcriptional activity ( 8 ) . VPA show anticancer effect , major HDAC inhibitor , single agent combine anticancer medication include myeloid lymphoid malignancy , breast cancer , prostate cancer , NPC ( 10-13 ) Long-term VPA treatment may cause central nervous system ( CNS ) dysfunction , liver toxicity , coagulopathy include thrombocytopenia platelet dysfunction ( 7 ) . 1.3 Ganciclovir ( GCV ) Valganciclovir ( VGC ) GCV antiviral agent use treatment prophylaxis cytomegalovirus infection solid organ transplantation recipient bone marrow transplantation ( 14 ) . GCV synthetic analogue 2'-deoxy-guanosine phosphorylated ganciclovir triphosphate , competitive inhibitor deoxyguanosine triphosphate ( dGTP ) incorporation DNA preferentially inhibit viral DNA polymerases cellular DNA polymerase , viral cell kinase . In addition , ganciclovir triphosphate serf poor substrate chain elongation , thereby disrupt viral DNA synthesis second route ( 15 ) . VGC , valyl ester prodrug GCV , high oral bioavailability 60 % similar efficacy GCV management cytomegalovirus infection ( 16 ) . The common side effect IV GCV fever leukopenia ( 16 ) . 1.4 Combination GEM , VPA GCV NPC treatment In EBV-related malignancy , antiviral drug exhibit direct effect cancer cell except use combine epigenetically active agent ( 17 , 18 ) . Recently , Wildeman et al , show efficacy combine chemotherapy GEM VPA GCV control locally advanced/metastatic NPC patient ( 13 ) . In article , GEM VPA could shift EBV latent phase lytic phase synergetic effect combine use . Further add GCV regimen could suppress virion formation . The combination therapy test three locally advanced/metastatic NPC patient show promising result tumor regressing/stable image plasma EBV DNA load monitor side effect Similar manageable side effect three drug combine treatment also prove Stoker et al ( 19 ) . These result encourage u develop practical regimen trial . 2 . Test product , dosage , mode administration : 2.1 . Chemotherapy regimen : Gemcitabine ( Gemmis injection，200 mg ) ( GEM , TTY ) + Valproic acid ( Depakine gastro-resistant tablet，200 mg ) ( VPA , Sanofi ) viral activation + Valganciclovir ( Valcyte film-coated tablets，450 mg ) ( VGC , Roche ) antiviral medication 2.2 . Dosage GEM : 600~1250 mg/m^2 , D1 &amp; D8 , intravenously . VPA : 12.5 mg/kg/day D1~14 , per o . VGC : ( 2~3 ) x 450mg/day D9~15 , per o . 1 . This treatment cycle 28 day repeat maximum 6 time . ( Q4wks/cycle , max : 6 cycle ) 2 . Four dosage GEM combine fixed dosage VPA VGC test 3 . The rationale seven day treatment duration VGC come ( A ) 7 day treatment duration valacyclovir herpes zoster immunocompetent patient ( 20 ) ( B ) overlap side effect myelosuppression GEM VGC ( 13 ) . 4 . Efficient dose intensity chemotherapy ( gemcitabine ) essential three combine drug regimen ( 21 ) trial start dose level 0 ( Gemcitabine 800 mg/m^2 ) 2.3 . Concomitant treatment 2.3.1 Permitted : The related treatment relieve symptom cause tumor . 2.3.2 Prohibited : 1 . Radiation therapy , operation , chemotherapy eradicate tumor 2 . Valganciclovir concomitant Imipenem-cilastatin could result convulsion ; zidovudine could result neutropenia ; Probenecid would increase toxicity ganciclovir 3 . Co-administration valproate amitryptyline/nortryptyline , warfarin need adjust necessary 4 . Co-administration valganciclovir didanosine , Mycophenolate mofetil , bone marrow suppression drug ( e.g. , dapsone , pentamidine , flucytosine , vincristine , vinblastine , adriamycin , amphotericin B , nucleoside analogue , hydroxyurea ) would need monitor seriously toxicity might increase 5 . All drug prohibit co-administration valproic acid absolutely 3 . Duration treatment : This treatment cycle 28 day repeat maximum 6 time . ( Q4wks/cycle , max : 6 cycle ) A standard 3 + 3 phase I dose escalation study design use ( 22 ) . A minimum three evaluable patient treat dose level . According Worst Toxicity CTCAE v4.03 Grade FDA indication gemcitabine , dose limit toxicity ( DLT ) trial determine first treatment cycle . In absence DLT , patient enrol next dose level . If 1 three patient DLT , cohort expand include six patient . If ≥2 patient experience DLT , maximum tolerate dose ( MTD ) exceed enrollment dose level stop . MTD define high dose level ≤1 6 patient experienced DLT . Only DLT occur first treatment cycle use determine MTD . 4 . Patient examination re-evaluation : Laboratory data complete blood count ( CBC ) /differential count ( DC ) , creatinine , alanine aminotransferase ( ALT ) routine check every week first 3 treatment cycle . During treatment course , grade 4 neutropenia grade 4 thrombocytopenia attack , laboratory check every 3 day recover pre-treatment baseline . Around 70 % responsive stable case could enrol 4th treatment cycle routine check laboratory data gemcitabine administration . Plasma EBV DNA copy number monitor cycle treatment . Systemic re-evaluation perform every three cycle treatment . Re-evaluation include physical examination , image study include CT/MRI head neck area , chest x-ray , abdominal echo , Gallium whole body tumor scan , blood exam include complete CBC count , biochemical profile , plasma EBV DNA copy number .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>1 . Have ability understand willingness sign write informed consent document 2 . Identified recurrent nasopharyngeal carcinoma distant metastasis male female subject fail 1st line therapy include radiotherapy , suitable radiotherapy unwilling receive radiotherapy , 1st line chemotherapy exclude gemcitabine , curative treatment option 3 . Biopsy confirm belong World Health Organization classification nasopharyngeal carcinoma type II type III 4 . Men woman age 20 80 year age ; female patient childbearing potential routinely consult obstetric doctor contraception need contraception least 6 month finish trial 5 . Adequate internal organ include liver , kidney bone marrow function white blood cell count &gt; 3,000/µL ; platelet count ≥100,000/µL ; absolute neutrophil count &gt; 1,500/µL total bilirubin &lt; 2.0 mg/dL , aspartate aminotransferase ( AST ) , alanine transaminase ( ALT ) &lt; 2.5x upper limit normal range ( ULN ) serum creatinine &lt; 2.0 mg/dL 6 . The daily performance status ECOG ≤ 2 point 1 . Pregnancy breastfeed woman , plan within six month pregnancy 2 . Contraindication Gemmis injection , Depakine gastroresistant tablet , Valcyte filmcoated tablet , include : Allergy Gemmis injection , Depakine gastroresistant tablet , Valcyte filmcoated tablet , similar drug Patients hepatic B C , patient human immunodeficiency virus , viral related disease receive antiviral treatment Acute chronic hepatitis relate NPC liver metastasis Using drug ineligible combination valproic acid , include mefloquine , St.John'sWort , lamotrigine , Topiramate , quetiapine , cyclosporin , hepatic enzymeinducing drug ( e.g. , phenytoin , carbamazepine phenobarbital , primidone , rifampin ) , enzyme inhibitor ( e.g. , felbamate ) , aspirin , cimetidine , erythromycin , carbapenem ( e.g. , Panipenem , Aztreonam , Imipenem , Meropenem ) , diazepam , ethosuximide , lamotrigine , phenytoin , nimodipine 3 . With insomnia , anxiety spiritual concern , receive mental illness treatment 4 . Has diagnose second cancer , except basal cell carcinoma 5 . Patients unsuitable trial , include : Patients significant disease PI evaluate high risk group patient Patients recover previous anticancer treatment Recent major surgery 6 . Patients creatinine clearance rate &lt; 40 ml/min</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Nasopharyngeal carcinoma</keyword>
	<keyword>EB virus</keyword>
	<keyword>metastasis</keyword>
	<keyword>recurrence</keyword>
	<keyword>cytolytic viral activation therapy</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>valproic acid</keyword>
	<keyword>ganciclovir</keyword>
	<keyword>valganciclovir</keyword>
</DOC>